Kanamycin
An aminoglycoside antibiotic used to treat serious bacterial infections including tuberculosis, working by binding to bacterial ribosomes to inhibit protein synthesis. It has also been studied as an inhaled therapy for asthma-related bacterial infections.
Molekularmasse
484,5000 g/mol
LogP
-6,90
TPSA
283,00 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Wirkmechanismus
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
2D-Struktur
Cite this structure
Embed this structure
SMILES
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
Molecular Formula
C18H36N4O11
HBD / HBA
11 / 15
Rotierbare Bindungen
6
Schwere Atome
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An aminoglycoside antibiotic used to treat serious bacterial infections including tuberculosis, working by binding to bacterial ribosomes to inhibit protein synthesis. It has also been studied as an inhaled therapy for asthma-related bacterial infections.
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Yes, Kanamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1384. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6032. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="kanamycin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/kanamycin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/kanamycin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/kanamycin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="kanamycin"></drugfyi-drug>